Industrial evolution: Indian pharma needs a major R&D-oriented reset

Glenmark’s progress with a cancer treatment shows the potential of Indian pharma to move from generics to drug discovery. With tech-enabled therapies evolving fast, new inflection points spell a variety of opportunities for startups and established players to leap ahead.

Opinion